Suven Life Science received two product patents in Russia and Australia for two of their new chemical entities (NCEs)

Suven has exclusive intellectual property for these products, which are used for the treatment of disorders associated with neuro – degenerative diseases and these patents are valid until 2023 through the exclusive internal discovery research efforts.

Product out of these inventories, which are in pre-clinical development, which are in pres-clinical development, may be out licensed at the stage of phase-I or phase II stage.